Management of Coronary Artery Calcification and Atherosclerosis

Risk Stratification Based on CAC Score

• The coronary artery calcium score (CACS) directly correlates with atherosclerotic burden and future cardiovascular risk, with a CACS of 0 indicating a very low 10-year event rate (1.5-3.0%), and statin therapy can be deferred in absence of smoking or family history of premature CAD, according to the Journal of Internal Medicine 1, 2
• A CACS of 1-99 indicates intermediate risk, with moderate-intensity statin therapy favored, especially in patients over 55 years, as recommended by the Journal of Internal Medicine 1, 2
• A CACS of 100-399 indicates definite atherosclerosis, with moderate-to-high intensity statin therapy mandatory, as stated in the Journal of Internal Medicine and Praxis Medical Insights 2, 4, 5
• A CACS of ≥400 indicates high risk, with a 17.9% death or MI rate, requiring aggressive preventive interventions, according to Praxis Medical Insights 3

Immediate Pharmacologic Management

• The European Society of Cardiology recommends initiating high-intensity statin therapy immediately for CACS >100, targeting LDL-C reduction of ≥50% from baseline, as stated in the European Heart Journal 4, 5, 6
• The American College of Cardiology recommends statin therapy in all patients with chronic coronary syndromes, as stated in the European Heart Journal 6

Comprehensive Risk Factor Control Targets

• The European Society of Cardiology recommends blood pressure control with a target <130/80 mmHg (general population) or 130-140 mmHg systolic in patients >65 years, as stated in the European Heart Journal 7, 8, 5
• The American Heart Association recommends beta-blockers and/or calcium channel blockers for symptomatic angina, as stated in the European Heart Journal 7, 8

Aggressive Lifestyle Modification

• The European Society of Cardiology recommends physical activity of 150 minutes of moderate-intensity aerobic exercise weekly, as stated in Praxis Medical Insights 4, 5
• The American Heart Association recommends a dietary pattern of Mediterranean or DASH diet, as stated in Praxis Medical Insights 4, 5

Risk-Enhancing Factors Requiring Intensified Management

• The European Society of Cardiology recommends assessing for family history of premature ASCVD, persistently elevated LDL-C, metabolic syndrome, chronic kidney disease, and chronic inflammatory disorders, as stated in the Journal of Internal Medicine and European Heart Journal 2, 7, 8

Calcium Distribution Assessment

• The European Society of Cardiology recommends requesting detailed information about calcium distribution across coronary vessels, as location significantly impacts risk, as stated in Praxis Medical Insights 4

Follow-Up Strategy and Monitoring

• The European Society of Cardiology recommends annual cardiovascular risk assessment, monitoring lipid panel, blood pressure, glucose metabolism, and medication adherence, as stated in Praxis Medical Insights and European Heart Journal 4, 5, 7, 8

Cost-Effectiveness and Numbers Needed to Treat

• The Journal of Internal Medicine states that CACS-guided therapy is most cost-effective in intermediate-risk patients with elevated CAC, with a number needed to treat (NNT) to prevent one ASCVD event over 5 years of 154 for CACS 0 versus 30 for CACS ≥100 1